Subject Index

ADCC, Herpes simplex virus, HSV glycoprotein, 279
Acyclovir, Herpes simplex virus, Guinea pig skin, Antiherpetic substance, Pyrophosphate analogue, 99
Acyclovir, Microencapsulated anti-viral assay in mice, Herpes simplex virus, 179
Adenovirus, Herpes simplex virus, Cytomegalovirus, Retrovirus, Pyrrolopyrimidine nucleoside, 263
Anti-HIV compound, Chinese herb, Polysaccharide, Purification, Chromatography, Spectroscopy, 107
Antiherpetic substance, Herpes simplex virus, Guinea pig skin, Pyrophosphate analogue, Acyclovir, 99
Antiviral treatment, Coxsackievirus, Lymphocyte subpopulation, Monoclonal antibody, Myocarditis, 129

Bovine, Tumor necrosis factor, Interferon, 71

Castanospermine, Cytomegalovirus, Glycoprotein complex, Inhibitor, glycoprotein processing enzyme, Deoxynojirimycin, 11
Cephalosporin derivative, DNA virus, 59
Chinese herb, Polysaccharide, Anti-HIV compound, Purification, Chromatography, Spectroscopy, 107
Chromatography, Chinese herb, Polysaccharide, Anti-HIV compound, Purification, Spectroscopy, 107
Coxsackievirus, Antiviral treatment, Lymphocyte subpopulation, Monoclonal antibody, Myocarditis, 129
Cytomegalovirus, Glycoprotein complex, Inhibitor, glycoprotein processing enzyme, Castanospermine, Deoxynojirimycin, 11
Cytomegalovirus, Herpes simplex virus, Adenovirus, Retrovirus, Pyrrolopyrimidine nucleoside, 263

DNA synthesis, 2′-Fluoro-5-substituted-ara-pyrimidine, Herpes simplex virus, Incorporation, Metabolism, Selective inhibition, 153
DNA virus, Cephalospirin derivative, 59
3-Deazauridine, Immunofluorescence antiviral assay, Pichinde virus, Ribavirin derivative, (S)-9-(2,3-dihydroxypropyl)adenine, 89
Deoxynojurimycin, Cytomegalovirus, Glycoprotein complex, Inhibitor, glycoprotein processing enzyme, Castanospermine, 11
(S)-9-(2,3-dihydroxypropyl)adenine, Immunofluorescence antiviral assay, Pichinde virus, Ribavirin derivative, 3-Deazauridine, 89

Enviroxime, Synergy, Interferon a, Rhinovirus, Prophylaxis, 141

2′-Fluoro-5-substituted-ara-pyrimidine, herpes simplex virus, Incorporation, Metabolism, Selective inhibition, DNA synthesis, 153

Genital wart, Interferon alpha-n1, Human papillomavirus, 41
Glycoprotein complex, Cytomegalovirus, Inhibitor, glycoprotein processing enzyme, Castanospermine, Deoxynojirimycin, 11
Glycoprotein, Immunotherapy, Recurrent genital herpes, 83
Glycyrrhizin, Human immunodeficiency virus, Protein kinase C, Virus adsorption, 289
Guinea pig skin, Herpes simplex virus, Antiherpetic substance, Pyrophosphate analogue, Acyclovir, 99

(R,S)-HPMPG, Herpesvirus, 235
HSV glycoprotein, Herpes simplex virus, ADCC, 279
HSV-2 infection, R-837, 209
Herpes simplex virus, 2′-Fluoro-5-substituted-ara-pyrimidine, Incorporation, Metabolism, Selective inhibition, DNA synthesis, 153
Herpes simplex virus, Microencapsulated anti-viral assay in mice, Acyclovir, 179
Herpes simplex virus, Cytomegalovirus, Adenovirus, Retrovirus, Pyrrolopyrimidine nucleoside, 263
Herpes simplex virus, ADCC, HSV glycoprotein, 279
Herpes simplex virus, OK-432, Immunomodulator, Immunosuppressed mice, 299
Herpesvirus, (*R,S*)-HPMPG, 235
Human immunodeficiency virus, Glycyrrhizin, Protein kinase C, Virus adsorption, 289
Human papillomavirus, Interferon alpha-n1, Genital wart, 41

IFN-γ, TNF, Potentiation, 1
rIFN-αCon1, Intranasal toxicity, 225
Immunofluorescence antiviral assay, Pichinde virus, Ribavirin derivative, 3-Deazauridine, (S)-9-(2,3-dihydroxypropyl)adenine, 89
Immunomodulator, OK-432, Herpes simplex virus, Immunosuppressed mice, 299
Immunosuppressed mice, OK-432, Immunomodulator, Herpes simplex virus, 299
Immunotherapy, Glycoprotein, Recurrent genital herpes, 83
In vivo efficacy, Murine cytomegalovirus, Interferon-γ, Mortality prophylaxis, 27
Incorporation, 2′-Fluoro-5-substituted-ara-pyrimidine, Herpes simplex virus, Metabolism, Selective inhibition, DNA synthesis, 153
Inhibitor, glycoprotein processing enzyme, Cytomegalovirus, Glycoprotein complex, Castanospermine, Deoxynojirimycin, 11
Interferon-γ, Murine cytomegalovirus, In vivo efficacy, Mortality, Prophylaxis, 27
Interferon alpha-n1, Genital wart, Human papillomavirus, 41
Interferon, Bovine, tumor necrosis factor, 71
Interferon α, Synergy, Enviroxime, Rhinovirus, Prophylaxis, 141
Interferon-inducing activity, Lipid A analog, Vaccinia virus, 167
Intranasal toxicity, rIFN-αCon1, 225
Isoflavan, Rhinovirus 1B, Isoflavene, 117
Isoflavene, Rhinovirus 1B, Isoflavan, 117

Lipid A analog, Vaccinia virus, Interferon-inducing activity, 167
Lymphocyte subpopulation, Coxsackievirus, Antiviral treatment, Monoclonal antibody, Myocarditis, 129

Metabolism, 2′-Fluoro-5-substituted-ara-pyrimidine, Herpes simplex virus, Incorporation, Selective inhibition, DNA synthesis, 153
Microencapsulated anti-viral assay in mice, Herpes simplex virus, Acyclovir, 179
Monoclonal antibody, Coxsackievirus, Antivirus treatment, Lymphocyte subpopulation, Myocarditis, 129
Mortality, Murine cytomegalovirus, Interferon-γ, In vivo efficacy, Prophylaxis, 27
Murine cytomegalovirus, Interferon-γ, In vivo efficacy, Mortality, Prophylaxis, 27
Myocarditis, Coxsackievirus, Antiviral treatment, Lymphocyte subpopulation, Monoclonal antibody, 129

OK-432, Immunomodulator, Herpes simplex virus, Immunosuppressed mice, 299

Phlebovirus, Ribamidine, Punta Toro virus, Ribavirin, 193
Pichinde virus, Immunofluorescence antiviral assay, Ribavirin derivative, 3-Deazauridine, (S)-9-(2,3-dihydroxypropyl)adenine, 89
Polysaccharide, Chinese herb, Anti-HIV, compound, Purification, Chromatography, Spectroscopy, 107
Potentiation, TNF, IFN-γ, 1
Prophylaxis, Murine cytomegalovirus, Interferon-γ, In vivo efficacy, Mortality, 27
Prophylaxis, Synergy, Interferon a, Enviroxime, Rhinovirus, 141
Protein kinase C, Glycyrrhizin, Human immunodeficiency virus, Virus adsorption, 289
Protein synthesis inhibition, Ribavirin nucleotide analog, 253
Punta Toro virus, Ribamidine, Phlebovirus, Ribavirin, 193
Purification, Chinese herb, Polysaccharide, Anti-HIV compound, Chromatography, Spectroscopy, 107
Pyrophosphate analogue, Herpes simplex virus, Guinea pig skin, Antiherpetic substance, Acyclovir, 99
Pyrrolopyrimidine nuceloside, Herpes simples virus, Cytomegalovirus, Adenovirus, Retrovirus, 263

R-837, HSV-2 infection, 209
Recurrent genital herpes, Glycoprotein, Immunotherapy, 83
Retrovirus, Herpes simplex virus, Cytomegalovirus, Adenovirus, Pyrrolopyrimidine nucleoside, 263
Rhinovirus 1B, Isoflavan, Isoflavene, 117
Rhinovirus, Synergy, Interferon α, Enviroxime, Prophylaxis, 141
Ribavirin derivative, Immunofluorescence antiviral assay, Pichinde virus, 3-Deazauridine, (S)-9-(2,3-dihydroxypropyl)adenine, 89
Ribavirin nucleotide analog, Protein synthesis inhibition, 253
Ribavirin, Ribamidine, Phlebovirus, Punta Toro virus, 193

Selective inhibition, 2′-Fluoro-5-substituted-ara-pyrimidine, Herpes simplex virus, Incorporation, Metabolism, DNA synthesis, 153
Spectroscopy, Chinese herb, Polysaccharide, Anti-HIV compound, Purification, Chromatography, 107

Synergy, Interferon α, Enviroxime, Rhinovirus, Prophylaxis, 141

TNF, IFN-γ, Potentiation, 1
Tumor necrosis factor, Bovine, Interferon, 71

Vaccinia virus, Lipid A analog, Interferon-inducing activity, 167
Virus adsorption, Glycyrrhizin, Human immunodeficiency virus, Protein kinase C, 289

Author Index

Al-Nakib, W., see Higgins, P.G., 141
Alaghamandan, H.A., see Smee, D.F., 253
Alaghamandan, H.A., see Smee, D.F., 263
Anderson, K.P., see Fennie, E.H., 27
Atchison, R.W., see Li, X.Q., 179

Baba, M., see Ito, M., 289
Babiuk, L.A., see Campos, M., 71
Barnard, D.K., see Sidwell, R.W., 193
Barnett, B.B., see Burns, III, N.J., 89
Barrow, G.I., see Higgins, P.G., 141
Bernstein, D.I., Loo, L.S. and Kohl, S.
Antibody to cloned HSV glycoproteins B and D plus adult human leukocytes protect neonatal mice from lethal HSV infection, 279
Bernstein, D.I., see Harrison, C.J., 209
Bernstein, D.I., see Myers, M.G., 83
Bielefeldt Ohmann, H., see Campos, M., 71
Bonnez, W., see Reichman, R.C., 41
Burns, III, N.J., Barnett, B.B., Huffman, J.H., Dawson, M.I., Sidwell, R.W., De Clercq, E. and Kende M.
A newly developed immunofluorscent assay for determining the Pichinde virus-inhibitory effects of selected nucleoside analogues, 89

Campos, M., Bielefeldt Ohmann, H., Hughes, G., Babiuk, L.A. and Lawman, M.J.P.
Studies on the in vitro biological activities of recombinant bovine tumor necrosis factor (rBoTNF) alpha. I. Synergistic antiviral efficacy of rBoTNF alpha, recombinant bovine interferon gamma (rBoIFN gamma) and their combination, 71
Chang, R.S., see Ngan, F., 107
Chou, T.-C., see Kong, X.-B., 153
Conti, C., Orsi, N. and Stein, M.L.
Effect of isoflavans and isoflavenes on rhinovirus 1B and its replication in HeLa cells, 117
Coppenhaver, D.H., see Hughes, T.K., 1
Cottagnoud, P., Neftel, K.A., Hany, M. and Zinkernagel, R.M.
Inhibition of HSV-1 and vaccinia virus replication by cephalosporin derivatives, 59

Dawson, M.I., see Burns, III, N.J., 89
De Clercq, E., see Burns, III, N.J., 89
De Clercq, E., see Ito, M., 289
DeLong, D.C., see Higgins, P.G., 141

Fanucchi, M.P., see Kong, X-B., 153
Farrar, G.H., see Taylor, D.L., 11
Feldman, A., see Terry, B.J., 235
Fellows, L.E., see Taylor, D.L., 11
Fennie, E.H., Lie, Y.S., Low, M.-A.L., Gribling, P. and Anderson, K.P.
Reduced mortality in murine cytomegalovirus infected mice following prophylactic murine interferon-γ treatment, 27
Field, A.K., see Terry, B.J., 235
Fohlman, J., see Ilbäck, N.-G., 129
Fox, J.J., see Kong, X.-B., 153
Frank, K.B., see Smee, D.F., 263
Friman, G., see Ilbäck, N.-G., 129

Gall, S.A., see Reichman, R.C., 41
Gorelik, E., see Li, X.Q., 179
Gribling, P., see Fennie, E.H., 27

Haffey, M.L., see Terry, B.J., 235
Hagen, M., see Terry, B.J., 235
Hany, M., see Cottagnoud, P., 59
Harrison, C.J., Jenski, L., Voychehovski, T. and Bernstein, D.I.
Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection, 209
Harrison, C.J., see Myers, M.G., 83
Hasegawa, A., see Ikeda, S., 167
Hayden, F.G., Innes, Jr., D.J., Mills, S.E. and Levine, P.A.
Intranasal tolerance and histophathologic effects of a novel synthetic interferon, rIFN-αCon1, 225
Helbig, B., see Wutzler, P., 99
Higgins, P.G., Barrow, G.I., Al-Nakib, W., Tyrrell, D.A.J., DeLong, D.C. and Lenox-Smith, I.
Failure to demonstrate synergy between interferon-α and a synthetic antiviral, enviroxime, in rhinovirus infection in volunteers, 141
Hirabayashi, K., see Ito, M., 289
Ho, M., see Li, X.Q., 179
Homma, J.Y., see Ideka, S., 167
Huffman, J.H., see Burns, III, N.J., 89
Huffman, J.H., see Sidwell, R.W., 193
Hughes, G., see Campos, M., 71
Hughes, T.K., Kaspar, T.A. and Coppenhaver, D.H.
Synergy of antiviral actions of TNF and IFN-γ: evidence for a major role of TNF-induced IFN-β, 1

Ikeda, S., Kumazawa, Y., Nishimura, C., Nakatsuka, M., Homma, J.Y., Kiso, M. and Hasegawa, A.
Enhancement of nonspecific resistance to viral infection by chemically synthesized lipid A-subunit analogs with different backbone structures and acyl groups, 167
Ikeda, S., Sai, K., Nishimura, C. and Yamamoto, A.
Antiherpes activity of the immunomodulator OK-432, a streptococcal preparation, in immunosuppressed mice (Short Communication), 299
Ilbäck, N.-G., Fohlman, J. and Friman, G.
The anti-inflammatory effect of LS 2616 and poly I:C in coxsackievirus B3 induced murine myocarditis, 129
Innes, Jr., D.J., see Hayden, F.G., 225
Ito, M., Sato, A., Hirabayashi, K., Tanabe, F., S., Baba, M., De Clercq, E., Nakashima, H. and Yamamoto, N.
Mechanism of inhibitory effect of glycyrrhizin on replication of hyman immunodeficiency virus (HIV), 289

Jeffries, D.J., see Taylor, D.L., 11
Jenski, L., see Harrison, C.J., 209

Kaspar, T.A., see Hughes, T.K., 1
Kende, M., see Burns, III, N.J., 89
Kini, G.D., see Smee, D.F., 253
Kiso, M., see Ikeda, S., 167
Kohl, S., see Bernstein, D.I., 279
Kong, X.-B., Scheck, A.C., Price, R.W., Vidal, P.M., Fanucchi, M.P., Watanabe, K.A., Fox, J.J. and Chou, T.-C.
Incorporation and metabolism of 2′-fluoro-5-substituted arabinosyl pyrimidines and their selective inhibition of viral DNA synthesis in herpes simples virus type 1 (HSV-1)-infected and mock-infected Vero cells cells, 153
Kucera, P., see Reichman, R.C., 41
Kumazawa, Y., see Ikeda, S., 167

Lawman, M.J.P., see Campos, M., 71
Lenox-Smith, I., see Higgins, P.G., 141
Levine, P.A., see Hayden, F.G., 225
Li, X.Q., Gorelik, E., Atchison, R.W., Ovejera, A. and Ho, M.
A new in vivo anti-viral assay using microencapsulated infected cell cultures, 179
Lie, Y.S., see Fennie, E.H., 27
Loo, L.S., see Bernstein, D.I., 279
Low, M.-A.L., see Fennie, E.H., 27

Mazina, K.E., see Terry, B.J., 235
McKernan, P.A., see Smee, D.F., 263
Meerbach, A., see Wutzler, P., 99
Micha, J.P., see Reichman, R.C., 41
Mills, S.E., see Hayden, F.G., 225
Mobberley, M.A., see Taylor, D.L., 11
Mounts, P., see Reichman, R.C., 41
Meyers, M.G., Bernstein, D.I., Harrison, C.J. and Stanberry, L.R.
Herpes simplex virus glycoprotein treatment of recurrent genital herpes reduces cervicovaginal virus shedding in guinea pigs, 83

Nakashima, H., see Ito, M., 289
Nakatsuka, N., see Ikeda, S., 167
Nash, R.J., see Taylor, D.L., 11
Neftel, K.A., see Cottagnoud, P., 59
Ngan, F., Chang, R.S., Tabba, H.D. and Smith, K.M.
Isolation, purification and partial characterization of an active anti-HIV compound from the Chinese medicinal herb Viola yedoensis, 107
Nishimura, C., see Ikeda, S., 167
Nishimura, C., see Ikeda, S., 299

Orsi, N., see Conti, C., 117
Ovejera, A., see Li, X.Q., 179

Pifat, D.Y., see Sidwell, R.W., 193
Pradel, W., see Wutzler, P., 99
Price, R.W., see Kong, X.-B., 153

Ramasamy, K., see Smee, D.F., 263
Reichman, R.C., Micha, J.P., Weck, P.K., Bonnez, W., Wold, D., Whisnant, J.K., Mounts, P., Trofatter, K.D., Kucera, P. and Gall, S.A.
Interferon alpha-n1 (wellferon0 for refractory genital warts: efficacy and tolerance of low dose systemic therapy, 41
Revankar, G.R., see Smee, D.F., 263
Robins, R.K., see Smee, D.F., 253
Robins, R.K., see Smee, D.F., 263
Ryder, T.A., see Taylor, D.L., 11

Sai, K., see Ikeda, S., 299
Sato, A., see Ito, M., 289
Scheck, A.C., see Kong, X.-B., 153
Shigeta, S., see Ito, M., 289
Sidwell, R.W., Huffman, J.H., Barnard, D.L. and Pifat, D.Y.
Effects of ribamidine, a 3-carboxamidine derivative of ribavirin, on experimentally induced Phlebovirus infections, 193
Sidwell, R.W., see Burns, III, N.J., 89

Slusarchyk, W.A., see Terry, B.J., 235
Smee, D.F., Alaghamandan, H.A., Kini, G.D. and Robins, R.K.
Antiviral activity and mode of action of ribavirin 5′-sulfamate against Semliki Forest virus, 253
Smee, D.F., McKernan, P.A., Alaghamandan, H.A., Frank, K.B., Ramasamy, K., Revankar, G.R. and Robins, R.K.
Antiviral activities of 2′-deoxyribofuranosyl and arabinofuranosyl analogs of sangivamycin against retro- and DNA viruses, 263
Smith, K.M., see Ngan, F., 107
Stanberry, L.R., see Myers, M.G., 83
Stein, M.L., see Conti, C., 117

Tabba, H.D., see Ngan, F., 107
Tanabe, F., see Ito, M., 189
Taylor, D.L., Fellows, L.E., Farrar, G.H., Nash, R.J., Taylor-Robinson, D., Mobberley, M.A., Ryder, T.A., Jeffries, D.J. and Tyms, A.S.
Loss of cytomegalovirus infectivity after treatment with castanospermine or related plant alkaloids correlates wit aberrant glycoprotein synthesis, 11
Taylor-Robinson, D., see Taylor, D.L., 11
Terry, B.J., Mazina, K.E., Tuomari, A.V., Haffey, M.L., Hagen, M., Feldman, A., Slusarchyk, W.A., Young, M.G., Zahler, R. and Field, A.K.
Broad-spectrun antiviral activity of the acyclic guanosine phosphate (R,S)-HPMPG, 235
Trofatter, K.F., see Reichman, R.C., 41
Tuomari, A.V., see Terry, B.J., 235
Tyms, A.S., see Taylor, D.L., 11
Tyrrell, D.A.J., see Higgins, P.G., 141

Ulbricht, A., see Wutzler, P., 99

Vidal, P.M., see Kong, X.-B., 153
Voychehovski, T., see Harrison, C.J., 209

Watanabe, K.A., see Kong, X.-B., 153
Weck, P.K., see Reichman, R.C., 41
Whisnant, J.K., see Reichman, R.C., 41
Wold, D., see Reichman, R.C., 41
Wutzler, P., Helbig, B., Ulbricht, A., Meerbach, A. and Pradel, W.
Therapeutic effect of pyrophosphate analogues on cutaneous herpes simplex virus type 1 infection in guinea pigs, 99

Yamamoto, A., see Ikeda, S., 299
Yamamoto, N., see Ito, M., 289
Young, M.G., see Terry, B.J., 235

Zahlerr, R., see Terry, B.J., 235
Zinkernagel, R.M., see Cottagnoud, P., 59